MedTrace Logo

Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β)

NCT06214338 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-05-20

No results posted yet for this study

Summary

The purpose of this study is to To study the blood bioavailability of a sustained-release β-alanine granulated supplement of two different doses (10 g and 20 g).

Conditions

  • Bioavailability

Interventions

DIETARY_SUPPLEMENT

Low dose

Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.

DIETARY_SUPPLEMENT

High dose

Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.

Sponsors & Collaborators

  • Universidad Católica San Antonio de Murcia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-12
Primary Completion
2024-03-18
Completion
2024-04-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06214338 on ClinicalTrials.gov